Allogenic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies

Scientists launched a Phase I trial to explore differences between autologous and allogeneic anti-CD7 CAR-T therapies in T cell acute lymphoblastic leukemia and lymphoma.